CONSULTATION QUESTIONS

Preferred Option

Question 1: Which is your preferred option?

Option 1 - Designated specialist service model

Option 2 - Development of a national Managed Clinical Network

Option 3 - Participation in a national Multi-Disciplinary Team

Option 4 - Development of a Regional approach

We would like to better understand the reason why you have chosen this option. The following questions aim to provide you the opportunity to provide further information in support of your choice.

Question 2: Do you consider that your preferred option will offer superior clinical outcomes?

Yes ☑ No ☐

Question 3: Do you consider that your preferred option will offer increased cost effectiveness?

Yes ☑ No ☐

Question 4: Do you consider that your preferred option is the best model in achieving a service which is deliverable?

Yes ☑ No ☐

Question 5: Do you feel that your preferred option will offer most benefit to the wider delivery of chronic pain management services in Scotland, for example the opportunity to develop skills?

Yes ☑ No ☐

If you have answered No to any of the questions above, please provide your reasons in the box below.

Comments are also welcomed here if you feel that any of the other options (please state which) would meet the needs described at Questions 2 through 5.

Comments
Question 6: Are there any other options which you feel should be considered that have not been included in the options presented?  
Yes [ ] No [x]

Question 7: Are there any other elements which should be included in a SIPMP which have not been identified in the current model?  
Yes [ ] No [x]

If you have answered Yes to Question 6 and/or 7 – please provide further information in the box below.

Comments

Equity of Access

A key aim of developing services is to ensure that there is equity of access across Scotland. Information at pages 11-12 of the consultation paper provides explanation of some of the points to consider. A full Equality Impact Assessment (for further information, please see Chapter 5 of the consultation paper) will be carried out on the preferred option identified through this consultation. To help inform this assessment, the following questions aim to seek views in this area.

Question 8: What are your views on using tele-health facilities to access / consult with specialist pain clinics?  
Comments

Question 9: What consideration should be given to potential travelling time / distance / costs? For example, how far/long would it be reasonable for someone to travel to access a SIPMP?  
Comments

Question 10: Is it reasonable that participants wait longer to access SIPMPs if delivered in Scotland because of smaller numbers of referrals?  
Yes [x] No [ ]

Comments
Question 11: What would be an acceptable time to wait to ensure that a participant joins the most appropriate SIPMP, for example one that is age or condition specific?

Comments

Question 12: Should the current service provided in Bath be retained to ensure availability of patient choice?

Yes ☑ No ☐

Question 13: Should participants of SIPMPs be offered the opportunity for their immediate carer/support provider to join the programme?

Yes ☑ No ☐

If you have answered Yes to Question 13, please provide further information in the box below. How do you feel the costs should be met – for example, through the NHS as part of the participants clinical costs, or through carer funding?

Comments

Question 14: If residential accommodation is required to participate in an SIPMP, this would be considered by the Equality Impact Assessment. As part of this assessment, are there any points you would specifically wish to be considered, for example distance from the point of delivery, cost, type of accommodation?

Comments

Local Skills, Resources and Capacity

Question 15: Options 2-4 provide three different models for the delivery of services at a local level. Do you feel that local teams have the skills, resource and capacity to deliver SIPMPs for Scotland locally?

Yes ☑ No ☐

If you have answered No to Question 15, please provide additional comments in the box below. For example, did this influence the choice of your preferred option?

Comments
Provision of Information

Question 16: What level of information should be provided to a potential participant? For example, should participants of SIPMPs receive copies of the clinical guidelines used by clinicians?

Comments

Commissioning and Governance

Question 17: Are there any other safeguards that should be included in any other commissioning agreement, for example, travel costs?

Comments

Business Impact Regulatory Assessment

Published with this consultation is a partial Business Impact Regulatory Assessment (BRIA) – for further information, please see Chapter 6 of the consultation paper. Once the preferred option is known, further consideration will be given as to the necessity (or not) of completing a full BRIA.

Question 18: In terms of potential impact of the models described in this consultation, are there any comments you would wish to be considered in terms of impact on any organisation that may be affected? This could include public sector, private sector or voluntary organisations.

Comments

If you wish to add any further comments regarding the issues raised in this consultation paper, please use the box below.

Comments